OBJECTIVE: To assess direct and indirect healthcare resource utilization and costs of privately insured US employees with ulcerative colitis (UC) from a societal perspective. RESEARCH DESIGN AND METHODS: Employees aged 18-64 with ≥ 2 UC diagnoses and no more than one diagnosis of Crohn's disease (CD) were identified from a large, de-identified, private insurance US claims database from January 1, 2005 through March 31, 2013. Patients with UC were matched 1:1 to non-IBD controls based on demographics and index date (a randomly selected UC diagnosis). All patients were required to have continuous eligibility for ≥ 1 year before (baseline period) and after (study period) the index date. Descriptive analyses compared baseline characteristics and study period outcomes. Multivariate cost analysis adjusted for baseline comorbidities. Sub-group analyses compared patients with moderate-to-severe UC with matched controls. MAIN OUTCOME MEASURES: Costs (2013 US dollars) were measured from a societal perspective, which included direct (patient and payer costs) and indirect (lost wages because of time away from work) costs. RESULTS: Patients with UC (n = 4314; mean age = 45.1 years, 63.6% male) had significantly higher baseline comorbidity rates compared with controls. In the study period, significantly more patients with UC (p < 0.0001) had higher hospitalization rates (16.9% vs 6.2%), emergency department visits (31.1% vs 22.0%), prescription drug use (95.3% vs 72.0%), and work loss (100% vs 81.4%). Patients with UC also had significantly higher adjusted total direct ($15,548 vs $4812) and indirect costs ($4125 vs $1961). Patients with moderate-to-severe UC (n = 1728) had significantly (p < 0.0001) higher hospitalization rates (26.5% vs 6.2%) and adjusted total direct ($23,085 vs $4932) and indirect costs ($5666 vs $1960). CONCLUSIONS: Patients with UC had higher resource utilization and direct and indirect costs compared with matched controls. The excess burden was greatest in patients with moderate-to-severe UC.
OBJECTIVE: To assess direct and indirect healthcare resource utilization and costs of privately insured US employees with ulcerative colitis (UC) from a societal perspective. RESEARCH DESIGN AND METHODS: Employees aged 18-64 with ≥ 2 UC diagnoses and no more than one diagnosis of Crohn's disease (CD) were identified from a large, de-identified, private insurance US claims database from January 1, 2005 through March 31, 2013. Patients with UC were matched 1:1 to non-IBD controls based on demographics and index date (a randomly selected UC diagnosis). All patients were required to have continuous eligibility for ≥ 1 year before (baseline period) and after (study period) the index date. Descriptive analyses compared baseline characteristics and study period outcomes. Multivariate cost analysis adjusted for baseline comorbidities. Sub-group analyses compared patients with moderate-to-severe UC with matched controls. MAIN OUTCOME MEASURES: Costs (2013 US dollars) were measured from a societal perspective, which included direct (patient and payer costs) and indirect (lost wages because of time away from work) costs. RESULTS:Patients with UC (n = 4314; mean age = 45.1 years, 63.6% male) had significantly higher baseline comorbidity rates compared with controls. In the study period, significantly more patients with UC (p < 0.0001) had higher hospitalization rates (16.9% vs 6.2%), emergency department visits (31.1% vs 22.0%), prescription drug use (95.3% vs 72.0%), and work loss (100% vs 81.4%). Patients with UC also had significantly higher adjusted total direct ($15,548 vs $4812) and indirect costs ($4125 vs $1961). Patients with moderate-to-severe UC (n = 1728) had significantly (p < 0.0001) higher hospitalization rates (26.5% vs 6.2%) and adjusted total direct ($23,085 vs $4932) and indirect costs ($5666 vs $1960). CONCLUSIONS:Patients with UC had higher resource utilization and direct and indirect costs compared with matched controls. The excess burden was greatest in patients with moderate-to-severe UC.
Entities:
Keywords:
Absenteeism; Colitis; Cost of illness; Economics; Health expenditures; Healthcare costs; Ulcerative
Authors: William V Williams; Joel Brind; Laura Haynes; Michael D Manhart; Hanna Klaus; Angela Lanfranchi; Gerard Migeon; Michael Gaskins; Elvis I Šeman; Lester Ruppersberger; Kathleen M Raviele Journal: Linacre Q Date: 2021-04-21
Authors: S Ballou; W Hirsch; P Singh; V Rangan; J Nee; J Iturrino; T Sommers; J Zubiago; N Sengupta; A Bollom; M Jones; A C Moss; S N Flier; A S Cheifetz; A Lembo Journal: Aliment Pharmacol Ther Date: 2018-02-07 Impact factor: 8.171
Authors: Hamed Khalili; Åsa H Everhov; Jonas Halfvarson; Jonas F Ludvigsson; Johan Askling; Pär Myrelid; Jonas Söderling; Ola Olen; Martin Neovius Journal: Aliment Pharmacol Ther Date: 2020-07-03 Impact factor: 9.524
Authors: Kenechukwu Chudy-Onwugaje; Alexander P Mamunes; David A Schwartz; Sara Horst; Raymond K Cross Journal: Inflamm Bowel Dis Date: 2021-02-16 Impact factor: 5.325
Authors: Alain Bitton; Katharine S Devitt; Brian Bressler; Joan Heatherington; Vipul Jairath; Jennifer Jones; Paul Moayyedi; Adam V Weizman; Catherine Dubé; Donald MacIntosh; Geoffrey C Nguyen Journal: J Can Assoc Gastroenterol Date: 2019-06-11